We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Continuing Its Aduhelm Draw-Down, Biogen Writes Off $275 Million in Inventory
Continuing Its Aduhelm Draw-Down, Biogen Writes Off $275 Million in Inventory
Biogen is writing off $275 million worth of Aduhelm (aducanumab) inventory — a formal declaration that the Alzheimer’s drug has no market value at all.